Literature DB >> 2931972

Effects of hematoporphyrin derivative and photodynamic therapy on atherosclerotic rabbits.

F Litvack, W S Grundfest, J S Forrester, M C Fishbein, H J Swan, E Corday, D M Rider, I S McDermid, T J Pacala, J B Laudenslager.   

Abstract

This study was performed to demonstrate selective uptake of hematoporphyrin derivative (HPD) within actively developing atheroma, to localize the site of uptake of HPD within the atheroma, and to determine the potential for photodynamic therapy (PDT) of atherosclerosis in the rabbit model. Fifteen rabbits were rendered atherosclerotic. Five rabbits received neither HPD nor PDT and 2 rabbits received HPD, 10 mg/kg intravenously, without subsequent irradiation. Eight other rabbits received 5 to 20 mg of HPD intravenously and subsequent intravascular 636-nm laser radiation to either the thoracic aorta or the aortic arch. A total of 32 to 288 J of laser energy was delivered through a 300-mu quartz fiber. All rabbits that received in vivo HPD had red fluorescence of their aortas when placed under ultraviolet light. The pattern of fluorescence corresponded precisely to the pattern of atheroma. In segments that received PDT, light microscopic examination revealed an accumulation of smooth muscle cells at the intimal surface. Fluorescence microscopy revealed a diminishing concentration gradient of HPD from intimal surface layers towards the media. Assessment of treated thoracic aortic segments revealed quantitative and qualitative differences compared with control segments. In the arch-treated segments, however, no changes were seen. It is concluded that HPD localizes within rabbit atheroma, can be detected by fluorescence and is deposited in a diminishing concentration gradient from lumen toward media. Irradiation with 636-nm light may induce qualitative and quantitative changes in atheroma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2931972     DOI: 10.1016/0002-9149(85)91032-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  10 in total

Review 1.  Photodynamic therapy: shedding light on restenosis.

Authors:  R Mansfield; S Bown; J McEwan
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

Review 2.  Endovascular surgery for peripheral arterial occlusive disease. A critical review.

Authors:  S S Ahn; D Eton; W S Moore
Journal:  Ann Surg       Date:  1992-07       Impact factor: 12.969

Review 3.  Nuclear medicine and atherosclerosis.

Authors:  H Sinzinger; I Virgolini
Journal:  Eur J Nucl Med       Date:  1990

Review 4.  Photodynamic therapy: a review.

Authors:  J S McCaughan
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

5.  Perforation thresholds and safety factors in in vivo coronary laser angioplasty.

Authors:  T J Bowker; K M Fox; F W Cross; P A Poole-Wilson; S G Bown; A F Rickards
Journal:  Br Heart J       Date:  1988-04

6.  Photodynamic sensitizers assay: rapid and sensitive iodometric measurement.

Authors:  J Mosinger; B Mosinger
Journal:  Experientia       Date:  1995-02-15

7.  Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics.

Authors:  Leanne B Josefsen; Ross W Boyle
Journal:  Theranostics       Date:  2012-10-04       Impact factor: 11.556

Review 8.  Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: role of activated neutrophils.

Authors:  W Sluiter; W J de Vree; A Pietersma; J F Koster
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

9.  ROS-responsive activatable photosensitizing agent for imaging and photodynamic therapy of activated macrophages.

Authors:  Hyunjin Kim; Youngmi Kim; In-Hoo Kim; Kyungtae Kim; Yongdoo Choi
Journal:  Theranostics       Date:  2013-12-01       Impact factor: 11.556

10.  Photodynamic therapy of normal rat arteries after photosensitisation using disulphonated aluminium phthalocyanine and 5-aminolaevulinic acid.

Authors:  W E Grant; P M Speight; A J MacRobert; C Hopper; S G Bown
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.